JNCI

Mammogen and Brilliantly Combine Forces to Advance Community Efforts for Breast Cancer Previvors and Survivors

Thursday, October 14, 2021 - 6:35pm

Brilliantly and Mammogen, Inc., two female-led womens health companies centered around breakthrough technologies designed to solve unmet clinical needs associated with breast cancer, announce a comprehensive partnership expected to improve quality of care for the breast cancer community, both inside and outside of the physicians office.

Key Points: 
  • Brilliantly and Mammogen, Inc., two female-led womens health companies centered around breakthrough technologies designed to solve unmet clinical needs associated with breast cancer, announce a comprehensive partnership expected to improve quality of care for the breast cancer community, both inside and outside of the physicians office.
  • The companys flagship genTRU-breastTM program leverages novel messenger RNA (mRNA) technology to non-invasively detect and diagnose breast cancer.
  • Brilliantly helps women with the transition from confronting breast cancer to embracing life through innovative products, thoughtful content, and relevant services.
  • The company has recently released their flagship technology, Brilliantly Warm, the first-ever wearable designed specifically for women who have had breast reconstruction surgery.

University of Rochester Researchers Link Chemo Brain to Lymphoma; Exercise Might Help Some Cancer Patients

Tuesday, October 5, 2021 - 12:00pm

Separately, investigators found that routine exercise prior to chemotherapy might prevent chemo brain among women with breast cancer, according to two recently published studies by the Wilmot Cancer Institute at the University of Rochester Medical Center .

Key Points: 
  • Separately, investigators found that routine exercise prior to chemotherapy might prevent chemo brain among women with breast cancer, according to two recently published studies by the Wilmot Cancer Institute at the University of Rochester Medical Center .
  • The National Cancer Institute estimates there are 17 million survivors today and expect 22 million by 2030.
  • Until now, most chemo brain research was focused on solid tumors, such as breast and prostate cancer.
  • A primary goal is to find ways to help older adults, who in general have the highest risk for cancer.

TYME Announces First Patient Dosed in Phase II OASIS Trial Evaluating the Potential Benefits of Oral SM-88 for Patients with Metastatic HR+/HER2- Breast Cancer After Treatment with a CDK4/6 Inhibitor

Monday, September 27, 2021 - 11:50am

We are pleased to be collaborating with Georgetown University to work toward transforming the treatment landscape for these metastatic HR+/HER2- patients.

Key Points: 
  • We are pleased to be collaborating with Georgetown University to work toward transforming the treatment landscape for these metastatic HR+/HER2- patients.
  • Dosing the first patient is a critical milestone in advancing oral SM-88 as a potential treatment option prior to chemotherapy for this patient population.
  • This is a significant opportunity for TYME, and we look forward to providing updates as the OASIS trial progresses, concluded Cunningham.
  • The Company is enrolling a Phase II study evaluating SM-88 in breast cancer (HR+/HER2-) and continues enrollment of a Phase II study in high-risk metastatic sarcomas.

Rapha Capital Leads New $3 Million Convertible Note Financing in Imagin Medical, Inc.

Monday, August 30, 2021 - 1:30pm

Concurrent with this financing, Kevin Slawin, M.D., a leading urooncologist and manager of the RCBVFI, will join Imagin's board of directors.

Key Points: 
  • Concurrent with this financing, Kevin Slawin, M.D., a leading urooncologist and manager of the RCBVFI, will join Imagin's board of directors.
  • Rapha Capital will receive warrants to acquire Shares of Imagin, as to 15,775,000 warrants exercisable at US $0.40 per Share for five years from the date of issue.
  • Rapha Capital will be granted a preemptive right to participate in any future financing undertaken by Imagin, so as to maintain its percentage equity interest.
  • In 2003, he was awarded theF.Brantley Scott, Jr., Award for Innovation and Creativity in Urology.Rapha Capital Management manages 13 legacy SPIVs, Rapha Capital Investment IXIII.

Imagin Medical Secures New $3 Million Convertible Note Financing

Thursday, August 26, 2021 - 9:56pm

Imagins previous convertible note offering, last referred to in the press release dated Feb. 18, 2021 , has been closed via a final tranche of $735,000, raising the total amount raised in that convertible note to $2,900,500.

Key Points: 
  • Imagins previous convertible note offering, last referred to in the press release dated Feb. 18, 2021 , has been closed via a final tranche of $735,000, raising the total amount raised in that convertible note to $2,900,500.
  • RCBVFIs new convertible note financing commits to investing US$3 million on the following terms:
    1.
  • We are excited to bring Dr. Slawin onto the leadership team as a board member at Imagin Medical, said Jim Hutchens, president and CEO of Imagin.
  • Imagin Medical is a surgical imaging company focused on advancing new methods of visualizing cancer during minimally invasive procedures.